SBE-β-CD (Sulfobutylether-β-Cyclodextrin) |
Catalog No.GC30001
One-Click Copy Product Info
|
SBE-β-CD, as a chemically modified β-CD, is a sulfobutylether β-cyclodextrin derivative.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 182410-00-0
Sample solution is provided at 25 µL, 10mM.
SBE-β-CD (Sulfobutylether-β-Cyclodextrin) is a β-cyclodextrin derivative with high water solubility, stability, and biocompatibility[1]. SBE-β-CD is negatively charged and can interact with positively charged small-molecule agonists/inhibitors via electrostatic attraction[2]. SBE-β-CD is primarily applied in research fields as a co-solvent and delivery vehicle for bioactive substances to improve the solubility and stability of poorly soluble active molecules, and is used to construct nano-delivery systems for controlled drug release[3,4,5].
In vitro, SBE-β-CD formed an inclusion complex with thymoquinone (TQ) at a 1:1 molar ratio (containing TQ at concentrations of 0.0013-100μg/mL, equivalent to 0.0079-609μM SBE-β-CD). Treatment of human colorectal carcinoma HCT-116 cells for 72h significantly reduced the IC50 value for TQ proliferation inhibition from 4.7 ± 0.21μg/mL to 1.2 ± 0.16μg/mL[6].
In vivo, a single intravenous dose of SBE-β-CD (600mg/kg) in rats exhibited rapid elimination with a half-life (T1/2) of only 18min, and was predominantly distributed in the extracellular fluid, with a steady-state volume of distribution (Vdss) of 300mL/kg and a plasma clearance of 9.8mL/min/kg[7].
References:
[1] Ren L, Yang X, Guo W, Wang J, Chen G. Inclusion complex of docetaxel with sulfobutyl ether β-cyclodextrin: preparation, in vitro cytotoxicity and in vivo safety. Polymers. 2020 Oct 13;12(10):2336.
[2] Sotthivirat S, Haslam JL, Stella VJ. Evaluation of various properties of alternative salt forms of sulfobutylether-β-cyclodextrin,(SBE) 7M-β-CD. International journal of pharmaceutics. 2007 Feb 7;330(1-2):73-81.
[3] Wang Y, Wei M, Zhang Y, Liu Y, Bi X, Fan X, Gou J, He H, Tang X, Zhang Y, Yin T. Ginkgolide B-cyclodextrin inclusion complexes: an encapsulation strategy for improved solubility and aerosol inhalation therapy in bronchial asthma. Drug Delivery and Translational Research. 2026 Mar 13:1-5.
[4] Bilia AR, Isacchi B, Righeschi C, Guccione C, Bergonzi MC. Flavonoids loaded in nanocarriers: an opportunity to increase oral bioavailability and bioefficacy. Food and Nutrition Sciences. 2014 Jul 1;5(13):1212.
[5] Wang Z, Li Y. Raloxifene/SBE-β-CD inclusion complexes formulated into nanoparticles with chitosan to overcome the absorption barrier for bioavailability enhancement. Pharmaceutics. 2018 Jun 28;10(3):76.
[6] Eid EE, Almaiman AA, Alshehade SA, Alsalemi W, Kamran S, Suliman FO, Alshawsh MA. Characterization of thymoquinone-sulfobutylether-β-cyclodextrin inclusion complex for anticancer applications. Molecules. 2023 May 15;28(10):4096.
[7] Stella VJ, He Q. Cyclodextrins. Toxicologic pathology. 2008 Jan;36(1):30-42.
| Cell experiment [1]: | |
|
Cell lines |
HCT-116 cells |
|
Preparation Method |
HCT-116 cells were treated with TQ/SBE-β-CD inclusion complex (1:1 molar ratio; containing TQ at 0.0013-100μg/mL, equivalent to 0.0079-609μM SBE-β-CD) for 72h, and cell viability was assessed using the MTT assay to determine the IC50 values. |
|
Reaction Conditions |
0.0079, 0.039, 0.1949, 0.9744, 4.8720, 24.36, 121.8, and 609μM; 72h |
|
Applications |
TQ/SBE-β-CD inclusion complex significantly enhanced the inhibitory effect on HCT-116 cells compared to free TQ, reducing the IC50 value from 4.7 ± 0.21μg/mL (free TQ) to 1.2 ± 0.16μg/mL after 72h of treatment. |
| Animal experiment [2]: | |
|
Animal models |
Rat |
|
Preparation Method |
Rats were administered a single intravenous injection of SBE-β-CD (600mg/kg), and pharmacokinetic parameters (T1/2, Vdss, and plasma clearance) and tissue distribution were evaluated. |
|
Dosage form |
600mg/kg; i.v. |
|
Applications |
A single intravenous injection of SBE-β-CD (600mg/kg) in rats exhibited rapid elimination with a T1/2 of 18min, a Vdss of 300mL/kg (corresponding to extracellular fluid volume), and a plasma clearance of 9.8mL/min/kg. |
References: [1] Eid EE, Almaiman AA, Alshehade SA, Alsalemi W, Kamran S, Suliman FO, Alshawsh MA. Characterization of thymoquinone-sulfobutylether-β-cyclodextrin inclusion complex for anticancer applications. Molecules. 2023 May 15;28(10):4096. [2] Stella VJ, He Q. Cyclodextrins. Toxicologic pathology. 2008 Jan;36(1):30-42. | |
| Cas No. | 182410-00-0 | SDF | |
| Formula | C42H70O35·xNa·x(C4H9O3S) | M.Wt | 2083-2257 |
| Solubility | Water : ≥ 500 mg/mL;DMSO : 5.625 mg/mL | Storage | Store at 2-8°C,protect from light |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 480.1 μL | 2.4004 mL | 4.8008 mL |
| 5 mM | 96 μL | 480.1 μL | 960.2 μL |
| 10 mM | 48 μL | 240 μL | 480.1 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)